Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia in… Ended

2024-515553-17-00 CNGA3-linked achromatopsia 2021-03-11
Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended

2024-513659-34-00 Relapsed/Refractory aggressive B-NHL 2021-02-12
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o… Ended

2023-505309-18-00 HER2-positive Metastatic Breast Cancer 2021-01-21
A Phase 1b/2 Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Ended

2023-503439-16-00 Multiple Myeloma 2020-12-29
A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended

2023-506839-15-00 Renal cell carcinoma 2020-12-21
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M… Ended

2024-514468-26-00 Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF 2020-12-04
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com… Ended

2024-512575-12-00 ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS 2020-11-25
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Chronic Lymphocytic Leukemia 2020-11-16
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Lymphoma of B-cell origin 2020-10-22
Treatment of advanced-stage malignancies harboring BRAF mutations with combination of Sorafenib and Trametinib: a multicenter study Ended

2024-512887-77-00 advanced-stage malignancies harboring BRAF mutations wi 2020-10-21
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in… Ended

2024-518506-41-00 metastatic castrate resistant prostate cancer 2020-10-05
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma Ended

2023-509350-63-00 Relapsed/Refractory marginal zone lymphoma 2020-09-16
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with F… Ended

2024-515379-36-00 Metastatic pancreatic ductal adenocarcinoma 2020-08-04
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i… Ended

2023-507236-20-00 Follicular Lymphoma (FL) 2020-07-28
Safety and potential efficacy of combining immunotherapy with chemotherapy and radiation for treatment of borderline resectable, nonresectab… Ended

2024-518173-34-00 Borderline resectable, locally advanced or metastatic p 2020-06-02
A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tu… Ended

2023-507703-63-00 Pediatric Patients with Advanced RET-Altered Solid or P 2020-05-04
Phase 1/2 Study of CLN-081 in Patients with Lung Cancer Ended

2024-516532-97-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 2020-03-26
TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment Ended

2024-515434-32-00 Low-risk gestational trophoblastic neoplasia 2020-02-12
A study of IMGN632 alone or in combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia Ended

2024-514197-50-00 CD123 positive Acute Myeloid Leukemia 2020-01-17
Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cance… Ended

2024-517705-93-00 Histologically or cytologically confirmed diagnosis of 2019-12-13
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have … Ended

2023-505088-35-00 Pediatric Solid tumors and primary central nervous syst 2019-12-12
CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended

2023-505219-19-00 Relapsed or refractory multiple myeloma (RRMM) and newl 2019-09-03
Treatment of severe congenital Brittle bone disease after or before and after birth. Ended

2023-504593-38-00 Osteogenesis Imperfecta (OI) type III and severe type I 2019-08-12
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l… Ended

2022-502616-37-00 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r 2019-07-30